The comparison levels of antiglaukoma medications consumed in U kraine, Estonia and Norway
DOI:
https://doi.org/10.24959/uekj.19.34Keywords:
market analysis, consumption of antiglaucoma medicationsAbstract
Glaucoma is the most common optical neuropathy in the world and is characterized by normal or elevated intraocular pressure. Drug therapy for glaucoma includes the appointment of antiglaucoma medications in the form of drops for local application.
Aim. To study the assortment and of antiglaucoma drugs consumption on the pharmaceutical market of Ukraine and to compare the indicators of volumes and structure of their consumption in Estonia and Norway.
Materials and methods. The calculation of consumed drugs was carried out on the basis of DDDs /1000 inhabitants/day or DID.
Results. During the perid of 2014-2017, antiglaucoma medications were presented on the market from 52 to 65 TH based on 13 INN mainly of foreign manufacturers (62-74 %). The vast majority of the range of drugs on the market belonged to timolol (43-19 %) and its combinations (14-22 %). Drug prices varied over a wide range, but increased every year. The total consumption of antiglaucoma drugs in Ukraine was low: from 6.11 DID (in 2014) to 10.03 DID (in 2017) and in terms of consumption inferior to consumption in Estonia by 4.5-3.7 times and in Norway by 3.1-2.4 times. Timolol preparations and their combinations were leaders in consumption, due to their affordable price, a significant amount of generic drugs and a high proven effectiveness in the treatment of glaucoma.
Conclusions. A sufficient assortment of antiglaucoma drugs is presented on the Ukrainian pharmaceutical market. Volumes of drug consumption in Ukraine were low and inferior to two European countries.
References
Vitovskaia, O. P. (2013). RMZh «Klinicheskaia Oftalmologiia», 3, 88–92.
Mishenin, A. B., Varyvonchyk, D. V. (2012). Visnyk sotsialnoi hihiieny ta orhanizatsii okhorony zdorov’ia Ukrainy, 1, 12–14.
Zhaboiedov, H. D., Skrypnyk, R. L., Baran, T. V. (2011). Oftalmolohiia: pidruchnyk. Kyiv: VSV “Medytsyna”, 261–306.
Kingman, S. (2004) Glaucoma is second leading cause of blindness globally. Bull. World Health Organ, 88(11), 887–888.
Povch, Z. V. (2014). Visnyk sotsialnoi hihiieny ta orhanizatsii okhorony zdorov’ia Ukrainy, 4(62), 8–11.
Rykov, S. A., Vitovskaia, O. P., Stepaniuk, G. I. (2009). Novosti glaukomy, 1, 34–35.
Novak, V. A., Lapykova, N. V., Hrybonosov, S. N. (2004). Materialy II Mizhnarodnoi naukovoi konferentsii oftalmolohiv Prychornomor’ia. (8-10.09.2004). Odesa, 78–79.
Kotvitska, A. A., Pastukhova, O. A. (2014). Farmakom, 3, 63–67.
Vitovskaia, O. P. (2009). Vestnik sotcialnoi gigieny i zdravookhraneniia, 4, 45–51.
Ustinov, O. V. (2015). Alhorytm dii likaria pry nadanni medychnoi dopomohy patsiientam iz pervynnoiu vidkrytokutovoiu hlaukomoiu (Nakaz MOZ U vid 23.11.2011 r. № 816). Ukrainskyi med. chasopys. Available at: https://www.umj.com.ua/wp/wp-content/uploads/2015/03/Glaukoma.pdf?upload=
Kotvitska, A. A., Pastukhova, O. A. (2014). Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky, 3(16), 97–101.
Prohramnyi kompleks «Apteka» kompanii «Morion». (n.d.). Available at: htts://pharmbase.com.ua/poisk
Morozov, A. M., Yakovlieva, L. V. Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., Dumenko, T. M., Matiashova, N. O., Adonkina, V. Yu., Chynush, I. V. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy. Kharkiv: Styl-Izdat, 34.
Derzhavna sluzhba statystyky Ukrainy. (n.d.). Available at: www.ukrstat.gov.ua
Statistics on Medicines in Estonia 2013-2016 (2017). Tartu, Green Print, 201.
Drug Consumption in Norway 2012–2016 (2016). Oslo, folkehelseinstitutt, 94.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
